Antibacterial Agents TRIZ Cases

Pure L-ergothioneine induces reactive oxygen species production in polymorphonuclear leukocytes to enhance immune responses.

Di-tert-butyl-4-methylphenol forms adducts with azole compounds to treat fungal infections while reducing cytotoxicity.

Phenylboronic acid groups anchor micelles to ocular mucin, overcoming rapid tear turnover barriers that limit traditional topical eye drop bioavailability.

Amphiphilic block copolymers encapsulate water-insoluble conjugated polymers into stable aqueous colloidal compositions.

Mitomycin C and cisplatin create DNA crosslinks to eradicate dormant bacterial persisters, resolving antibiotic tolerance in recalcitrant infections.

A 2-alkoxy[4,3:6,4-terpyridine]-3-carbonitrile compound inhibits bacterial and fungal growth through a terpyridine-coumarin hybrid structure.

Modified AdB-2/3 fiber polypeptides enhance desmoglein 2 affinity, disrupting tight junctions to deliver therapeutics to epithelial cancer cells.

Pectin coats resveratrol crystals to form granules, overcoming poor powder fluidization for tablet manufacturing.

Targeting conserved OppA and LapB proteins triggers a Th17 response that overcomes sequence variation to provide broad cross-strain protection.

Digestive enzymes degrade cell walls to treat resistant E. coli strains.

Novel pyridinone compounds inhibit the bacterial enzyme Fab I to block fatty acid biosynthesis.

Gamma cyclodextrin forms inclusion complexes with macrolides, preventing oxidative degradation and maintaining bioavailability.

Silicon-based siosomes replace unstable phospholipids to prevent drug leakage and enable autoclaving while inhibiting nucleic acid synthesis.

Bacillus subtilis strain PS-216 spores resist gastric conditions to reduce Campylobacter jejuni colonization and enhance broiler growth.

Aryl guanidine compounds inhibit mitochondrial F1F0-ATPases to selectively induce apoptosis in diseased cells, sparing healthy tissue and reducing resistance.

Morpholino oligonucleotides target conserved influenza viral RNA regions to inhibit replication, overcoming strain-specific vaccine limitations.

Recombinant chimeric proteins combined with non-metabolizable mineral oil adjuvants provide long-lasting immunity against contemporary West Nile Virus strains.

A beta-1,6-glucan composition enriched with O-acetyl groups stimulates antigen-specific immune responses.

Segmented molecules use protease cleavage to activate siRNA, ensuring gene suppression despite target mutations.

Novel azetidine derivatives modulate sphingosine-1-phosphate receptors to treat cardiovascular and inflammatory disorders.

A therapeutic antibody engineered with a specific glycosylation site resists enzymatic modification while endogenous serum antibodies are degraded.

Peptide sequences with cationic residues target bacterial membranes while sparing human cells, bypassing antibiotic resistance.